RAD-140 (Testolone)
Testolone · RAD140
RAD-140 (Testolone) is a non-steroidal selective androgen receptor modulator (SARM) originally developed by Radius Health for the treatment of androgen receptor-positive breast cancer and investigated for muscle wasting conditions. It binds the androgen receptor with high affinity and selectivity, producing strong anabolic effects in skeletal muscle with less prostate and seminal vesicle activity than testosterone. Among SARMs, RAD-140 is considered one of the most potent and testosterone-like on a milligram basis.
Take once daily at a consistent time given the 16-20 hour half-life. Many users dose in the morning to align peak activity with training later in the day. Plan comprehensive pre, mid, and post-cycle bloodwork (total and free testosterone, LH, FSH, estradiol, lipid panel, ALT/AST, CBC). Plan a full PCT (Nolvadex 20mg/day or Clomid 25mg/day for 4 weeks) for every cycle.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
How it works
RAD-140 binds the androgen receptor (AR) with high affinity - comparable to or exceeding testosterone in binding assays - and acts as a potent tissue-selective partial agonist. It preferentially drives anabolic signaling in skeletal muscle while producing less androgenic activity in prostate tissue than testosterone, though it is more androgenic than ostarine or ligandrol at equivalent anabolic doses.
As a non-steroidal compound it does not aromatize to estrogen and does not convert to DHT. This eliminates typical aromatase and 5-alpha-reductase-driven side effects at standard doses. However, RAD-140 is notable for producing stronger and longer HPT-axis suppression than most SARMs, and androgenic side effects (aggression, hair loss in predisposed users) are more commonly reported.
Hepatic effects are more pronounced than with milder SARMs. ALT and AST elevation is routinely reported at athletic doses (10-20mg daily) and the FDA has flagged case reports of significant drug-induced liver injury in gray-market users. Endogenous testosterone, LH, and FSH suppression is substantial and typically requires a full SERM-based PCT. Some users report mood and emotional changes (flattening, aggression, reduced emotional range) that reverse off-cycle.
What to expect
First 1-2 weeks: rapid onset. Strength, aggression, and confidence in the gym apparent by end of week 1 for many users. Some early water-weight shift.
Weeks 3-5: visible muscle gain, continued strength climb, improved pump. Mid-cycle liver panel essential.
Weeks 6-8: peak benefits. Cycle end recommended by week 8 due to hepatic and HPT burden. PCT begins immediately after last dose.
Evidence
References for this compound are being re-checked against their source records. We are not showing them until each one is confirmed to support the claim it sits under.
Side effects & safety
Commonly reported
- Pronounced suppression of endogenous testosterone (deeper than ostarine/ligandrol, PCT required)
- Lipid profile changes (HDL drop, LDL rise)
- ALT/AST elevation
- Increased aggression or mood changes
- Mild acne or oily skin in predisposed users
Less common & notes
- Libido changes (up early, then dip during suppression), accelerated hair loss in genetically predisposed users (more than milder SARMs given higher androgenic activity), mild blood pressure elevation, headache, mood flattening or reduced emotional range, insomnia, testicular softening.
- In women: significant virilization risk - generally not recommended.
- FDA has flagged case reports of serious drug-induced liver injury in supplement users; product purity is a major confounder but direct hepatotoxicity is possible at athletic doses.
- Rare but serious: cholestatic hepatitis, persistent HPT suppression requiring extended recovery.
Pharmacokinetics
High oral bioavailability
Per dose - supports once daily dosing
Hepatic metabolism via CYP3A4. Renal excretion of metabolites.
Storage. Store at controlled room temperature (20-25°C / 68-77°F). Protect from moisture and light. Keep capsules in original container with desiccant when available. Liquid suspensions should be kept sealed and used within 12 months of opening. Shelf life typically 2-3 years from manufacture date for capsules, 1-2 years for liquid. Keep out of reach of children.
Regulatory status
RAD-140 (Testolone) is NOT FDA-approved for any indication. The FDA has issued public warnings citing case reports of liver injury and other serious adverse events in supplement users. Classified as a research chemical in the United States - not a controlled substance federally as of this writing, but banned by WADA, USADA, the NCAA, and most professional sports leagues. Some US states have introduced legislation restricting SARM sales. Use falls outside regulated medical practice.
Put it to work
Calculate, log & track
Open RAD-140 (Testolone) straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open RAD-140 (Testolone) in the app →Go deeper
The guide & community
The complete RAD-140 (Testolone) walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗